Somatostatin Analogs (SSAs) as Effective Treatment of Resectable, non Metastatic, non Functioning Pancreatic Neuroendocrine Tumors (NF-pNETs) in Patients Unfit for Surgery. A Case Series. Abstract #2243

Introduction: SSAs are used to treat symptomatic functioning pNETs and to prolong progression free survival in metastatic, G1/G2, somatostatin receptor-positive pNETs. Pancreatic surgery is burdened with important morbidity and mortality, especially in patients with increased anaesthesiological risk.
Aim(s): We report the cases of patients unfit for surgery presenting resectable G1 NF-pNETs, who received SSAs as first treatment.
Materials and methods: From August 2015 to November 2016 we evaluated 7 patients with multiple comorbidities (ASA 3), affected by non metastatic, non functioning, G1 (Ki 67 1-2%) resectable pNETs. Mean age was 66 years (range 48-83), 4 of them were obese (mean BMI 31 kg/m2 ,range 27-35). In 4 cases the lesion was in the pancreatic head, in 1 case in the body, 2 cases had multiple lesions. The mean diameter of the lesions, at CT and MRI scans, was 32.14 mm (range 23 - 56). All the cases showed pathological uptake on Gallium PET/CT scans. The patients didn’t undergo surgery, and were treated with SSAs (Octreotide LAR 30 mg or Lanreotide LAR 120 mg), one injection every 28 days.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Chiara Nessi

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1476 Efficacy of Everolimus and Somatostatin Analogs as Single Agents or in Combination in Human Pancreatic Neuroendocrine Tumors Primary Cultures
Introduction: Among the therapeutic options available for the treatment of neuroendocrine tumors, one targeted therapy, everolimus (RAD) has been approved for advanced progressive pancreatic neuroendocrine tumors (pNETs). It improve progression free survival but is not curative. Alterations of the PI3K/Akt/mTOR pathway in pNETs have given the rational for the use of this signaling pathway inhibitors.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: doctor Corinne Gerard
#2081 Preclinical Testing of SSA Compounds in a Model of Pancreatic Neuroendocrine Tumors to Optimize Scheduling and Drug Exposition
Introduction: Somatostatin analogues (SSA) such as Octreotide and Lanreotide have demonstrated a significant benefit in Neuroendocrine Tumors, particularly in the well/moderately differentiated types. Nevertheless, there are still several aspects of SSA treatments that remain unsolved, such as drug exposition in patients and schedule optimization.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: PhD Oriol Casanovas
#114 Downstaging of a gastroenteropancreatic neuroendocrine tumor after combination therapy of temozolomide, Bevacizumab and long-acting somatostatin analogs
Introduction: Patients with gastroenteropancreatic endocrine (GEP) tumors and progressive disease have been treated with several chemotherapeutic regimens with variable responses and considerable toxicity. Recent studies have shown that GEP tumors may respond to therapy with anti-angiogenic agents, mainly as a result of their increased vascularity.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Stavroula Antoniou
#831 Overall Survival (OS) as a Function of the Number of Therapeutic Lines in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors (WDpNET)
Introduction: At least 9 therapeutic options are now available for unresectable WDpNET patients. Whether all lines can be administrated before tumor or toxic-related deaths is currently unknown.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Others
Presenting Author: Amandine Berdelou
Keywords: pNets
#2228 Prognostic Value of Lymph Node Status and Extent of Lymphadenectomy in Non Functioning Pancreatic Neuroendocrine Tumors: Outcome Analysis from 378 Consecutive Resections in a High-Volume Institution
Introduction: The optimal management of regional lymph nodes during resections of Pancreatic Neuroendocrine Tumors (pNETs) remains controversial. Conflicting data exist on predictors of LN metastases (LNM) and their impact on survival
Conference: 15th Annual ENETS conference (2018)
Category: Surgical treatment and Ablative Therapies
Presenting Author: doctor Anna Malpaga
Authors: Malpaga A, Miotto M, Elio G, Nessi C, ...
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.